

[Zn<sub>4</sub>(L<sup>2</sup>)<sub>4</sub>](PF<sub>6</sub>)<sub>8</sub> (**2**) was prepared similarly, but the reaction mixture needed to be refluxed and the subsequent PF<sub>6</sub><sup>−</sup> salt recrystallized from MeCN/Et<sub>2</sub>O. The yields in both cases exceeded 95 %. **ATTENTION:** The intermediate perchlorate salts of the complexes are explosive.

Received: March 19, 2001 [Z16796]

- [1] a) B. Hasenknopf, J.-M. Lehn, B. O. Kneisel, G. Baum, D. Fenske, *Angew. Chem.* **1996**, *108*, 1987–1990; *Angew. Chem. Int. Ed. Engl.* **1996**, *35*, 1838–1840; b) O. Mamula, A. von Zelewsky, G. Bernadelli, *Angew. Chem.* **1998**, *110*, 302–305; *Angew. Chem. Int. Ed.* **1998**, *37*, 289–293; c) O. Mamula, A. von Zelewsky, T. Bark, G. Bernadelli, *Angew. Chem.* **1999**, *111*, 3129–3133; *Angew. Chem. Int. Ed.* **1999**, *38*, 2945–2948.
- [2] a) M. Ruben, E. Breuning, J.-P. Gisselbrecht, J.-M. Lehn, *Angew. Chem.* **2000**, *112*, 4312–4315; *Angew. Chem. Int. Ed.* **2000**, *39*, 4139–4142; b) A. M. Garcia, F. J. Romero-Salguero, D. M. Bassani, J.-M. Lehn, G. Baum, D. Fenske, *Chem. Eur. J.* **1999**, *5*, 1803–1808, and references therein; c) S. Toyota, C. R. Woods, M. Benaglia, R. Haldimann, K. Wärnmark, K. Hardcastle, J. S. Siegel, *Angew. Chem.* **2001**, *113*, 773–776; *Angew. Chem. Int. Ed.* **2001**, *40*, 751–754; d) J. R. Galán-Mascarós, K. R. Dunbar, *Chem. Commun.* **2001**, 217–218.
- [3] In contrast, the isomeric ligand 2,3-bis(2,2'-bipyridin-6-yl)pyrazine with Co<sup>2+</sup> ions yields a dinuclear “metalloacyclopentane”. F. Heitzler, T. Weyhermüller, *J. Chem. Soc. Dalton Trans.* **1997**, 3653–3654.
- [4] The solid-state structure of a related trimeric complex obtained from ZnCl<sub>2</sub> and 2,5-bis(2-pyridyl)pyrazine has been reported: A. Neels, H. Stoeckli-Evans, *Inorg. Chem.* **1999**, *38*, 6164–6170.
- [5] O. Mamula, F. J. Monlien, A. Porquet, G. Hopfgartner, A. E. Merbach, A. von Zelewsky, *Chem. Eur. J.* **2001**, *7*, 533–539.
- [6] Crystal data for **1**: C<sub>109</sub>H<sub>106</sub>F<sub>48</sub>N<sub>26</sub>O<sub>8</sub>P<sub>8</sub>Zn<sub>4</sub>, *M<sub>r</sub>* = 3323.39; pale yellow block, 0.40 × 0.40 × 0.30 mm<sup>3</sup>, obtained from MeNO<sub>2</sub>/EtOH/MeOH by the diffusion of Et<sub>2</sub>O. *μ* = 0.947 mm<sup>−1</sup>, *F*(000) = 6688. Monoclinic, space group C2/c, *a* = 19.8633(12), *b* = 31.1631(17), *c* = 22.8036(12) Å, *α* = 90°, *β* = 110.562(6)°, *γ* = 90°, *V* = 13216.2(13) Å<sup>3</sup>, *Z* = 4, *ρ*<sub>calcd</sub> = 1670 kg m<sup>−3</sup>. Data collection at 153 K on a Stoe Image Plate Diffraction system, by using graphite-monochromated Mo<sub>Kα</sub> radiation (*λ* = 0.71073 Å). Image plate distance: 70 mm, *φ* oscillation scans 0–190°, step *Δφ* = 1°, 2*θ* = 3.27–52.1°, *d*<sub>max</sub>/*d*<sub>min</sub> = 12.45/0.81 Å. A total of 49250 reflections of which 12828 were independent and used to refine 857 parameters. 6968 observed reflections with *I* > 2*σ*(*I*). *R* = 0.0748, *wR*<sub>2</sub> = 0.2002 (observed); *R* = 0.1216, *wR*<sub>2</sub> = 0.2214 (all data). The structure was solved by direct methods (SHELXS-97) and refined anisotropically on *F*<sup>2</sup> (SHELXL-97). Hydrogen atoms were included in calculated positions and treated as riding atoms. Max./min. residual electron density +1.274/−1.056 e Å<sup>−3</sup>. One molecule of CH<sub>3</sub>NO<sub>2</sub> was located in the asymmetric unit together with a considerable amount of highly disordered, and difficult to identify, solvent. The SQUEEZE routine in PLATON (A. L. Spek, *Acta Crystallogr. Sect. A* **1990**, *46*, C43) was used to modify the HKL data and indicated the presence of the equivalent of 515 electrons per unit cell. This value was equated to one MeOH, one EtOH, and two Et<sub>2</sub>O molecules per molecule of complex. b) Crystallographic data (excluding structure factors) for the structures reported in this paper have been deposited with the Cambridge Crystallographic Data Centre as supplementary publication nos. CCDC-159770 (**1**) and -159771 (**2**). Copies of the data can be obtained free of charge on application to CCDC, 12 Union Road, Cambridge CB21EZ, UK (fax: (+44) 1223-336-033; e-mail: deposit@ccdc.cam.ac.uk).
- [7] K. R. Dunbar and co-workers have reported the tetrameric complex [Ni<sub>4</sub>(bptz)<sub>4</sub>(MeCN)<sub>8</sub>](BF<sub>4</sub>)<sub>8</sub> (bptz = 3,6-bis(pyridyl)-1,2,4,5-tetrazine): C. S. Campos-Fernandez, R. Clérac, K. R. Dunbar, *Angew. Chem.* **1999**, *111*, 3685–3688; *Angew. Chem. Int. Ed.* **1999**, *38*, 3477–3479. The group of X.-H. Bu and M. Mitsuhiro obtained the tetrameric Zn<sup>2+</sup> complex from the same ligand, and this complex resolved spontaneously into enantiomers upon crystallization: X.-H. Bu, M. Hiromasa, K. Tanaka, K. Biradha, S. Furusho, M. Shionoya, *Chem. Commun.* **2000**, 971–972.
- [8] a) U. Knof, A. von Zelewsky, *Angew. Chem.* **1999**, *111*, 312–333; *Angew. Chem. Int. Ed.* **1999**, *38*, 302–322; b) A. von Zelewsky, O. Mamula, *J. Chem. Soc. Dalton Trans.* **2000**, 219–231.

[9] Crystal data for **2**: C<sub>169</sub>H<sub>199</sub>F<sub>48</sub>N<sub>31</sub>O<sub>12</sub>P<sub>8</sub>Zn<sub>4</sub>, *M<sub>r</sub>* = 4277.83; pale yellow rod, 0.30 × 0.20 × 0.15 mm<sup>3</sup>, from MeCN/MeOH/Et<sub>2</sub>O. *μ* = 0.605 mm<sup>−1</sup>, *F*(000) = 2198. Triclinic, space group *P*1, *a* = 13.7635(10), *b* = 18.9612(11), *c* = 21.8334(16) Å, *α* = 102.476(8)°, *β* = 106.002(9)°, *γ* = 90.240(8)°, *V* = 5335.5(6) Å<sup>3</sup>, *Z* = 1, *ρ*<sub>calcd</sub> = 1331 kg m<sup>−3</sup>, data collection (at 153 K) and refinement as for **1**. 2*θ* = 3.72–51.82°, *φ* = 0–200°, *Δφ* = 1°. In total 42111 reflections were collected of which 34862 were independent and used to refine 1622 parameters. *R* = 0.0717 and *wR*<sub>2</sub> = 0.1604 for 13535 observed reflections (*I* > 2*σ*(*I*)); *R* = 0.1711 and *wR*<sub>2</sub> = 0.1871 for all data. Disordered solvent was equated to 7 MeCN, 3 MeOH, and 11 H<sub>2</sub>O molecules. The PF<sub>6</sub><sup>−</sup> ions are disordered and suffer from thermal motion. Flack parameter<sup>[10]</sup> *x* = 0.016(13). Max./min. residual electron density +0.811/−0.441 e Å<sup>−3</sup>.<sup>[6b]</sup>

[10] H. D. Flack, *Acta Crystallogr. Sect. A* **1983**, *39*, 876–881.

## By Overexpression in the Yeast *Pichia pastoris* to Enhanced Enantioselectivity: New Aspects in the Application of Pig Liver Esterase\*\*

Anna Musidlowska, Stefan Lange, and Uwe T. Bornscheuer\*

Dedicated to Professor Günter Schmidt-Kastner on the occasion of his 75th birthday

Lipases and esterases can be used as efficient biocatalysts for the preparation of a wide variety of optically pure compounds.<sup>[1]</sup> Whereas a range of lipases—especially of microbial origin—are commercially available, only a few esterases can be obtained for the kinetic resolution of racemates or desymmetrization. In the majority of publications, pig liver esterase<sup>[2]</sup> (PLE) is used, which is isolated from pig liver by extraction. Although it has been demonstrated that this preparation can convert a broad range of compounds at partially very high stereoselectivity, its application is connected with a number of disadvantages. Besides a variation of the esterase content between different batches, the presence of other hydrolases particularly has to be considered as problematic with respect to stereoselectivity.<sup>[3]</sup> Furthermore, it has been shown that PLE consists of several isoenzymes,<sup>[4]</sup> which in part differ considerably in their substrate specificity. Thus, electrophoretic separation by isoelectric focusing enabled access to PLE fractions that,

[\*] Prof. Dr. U. T. Bornscheuer, A. Musidlowska  
Institute of Chemistry and Biochemistry  
Department of Technical Chemistry and Biotechnology  
Greifswald University  
Soldmannstrasse 16, 17487 Greifswald (Germany)  
Fax: (+49) 3834-86-4373  
E-mail: bornsche@mail.uni-greifswald.de  
S. Lange  
Institute of Technical Biochemistry  
Stuttgart University (Germany)

[\*\*] We thank the Konrad-Adenauer foundation (St. Augustin, Germany) for a stipend to A.M., Prof. R. D. Schmid (Institute of Technical Biochemistry, Stuttgart University) for his support and discussions, and A. Gollin for the synthesis of the acetates.

besides other substances, preferentially converted butyrylcholine (an action comparable to butyrylcholine esterase), proline- $\beta$ -naphthylamide, and methylbutyrate.<sup>[5a,b]</sup> Öhrner and co-workers<sup>[5c]</sup> not only found an influence by the chainlength of *p*-nitrophenyl esters on the activity of different PLE fractions, but also a significant change in enantioselectivity in the hydrolysis of prostereogenic substrates. In contrast, Jones and co-workers reported that different isoenzymes show almost no differences in the stereoselective hydrolysis of several monocyclic and acyclic diesters. Only differences in activity were reported.<sup>[6]</sup>

The production of enzymes at stable and defined composition can be achieved by overexpression of the encoding genes in suitable host organisms such as *Escherichia coli*, *Pichia pastoris*, or *Aspergillus oryzae*. Indeed, several esterases<sup>[7]</sup> and lipases<sup>[8]</sup> are thus produced. The cloning of putative pig liver esterase genes has already been described: Takahashi and co-workers<sup>[9a,b]</sup> cloned a gene, isolated from pig liver, which encoded for a proline- $\beta$ -naphthylamidase. Later, the same group<sup>[10]</sup> and Heymann's group<sup>[11]</sup> demonstrated that, with high probability, it was actually PLE that was cloned. The same holds true for a glycerolester hydrolase,<sup>[12]</sup> which is distinguished only by 16 amino acids from the protein sequence published by Takahashi and co-workers. However, the functional expression of active enzymes was not reported by any of the research groups.

We have now succeeded for the first time in the overexpression of active PLE in the yeast *Pichia pastoris*.<sup>[13]</sup> Thus, we can now produce recombinant PLE (rPLE) at stable product quality without interfering influences of other isoenzymes and hydrolases. The rPLE shows almost identical pH and temperature profiles<sup>[13]</sup> and a similar substrate spectrum in the hydrolysis of simple (achiral) esters and triacylglycerides compared to nonrecombinant PLE (Figure 1). It has to be emphasized that only rPLE does not cleave triolein, which is a typical lipase substrate. This exemplifies the impurity of commercial preparations containing other hydrolases. Beside a biochemical characterization, we were especially interested in the stereoselectivity of rPLE in the conversion of chiral substrates in comparison to commercial preparations,<sup>[14]</sup> as this represents by far the most important area of application for PLE.

Whereas in the PLE-catalyzed kinetic resolution of (*R,S*)-(1-phenylethyl)acetate (**1**) similar enantioselectivities<sup>[15]</sup> between  $E = 5.7$  and  $7.9$  were determined in all cases (Table 1), significantly higher enantioselectivities were found in the hydrolysis of (*R,S*)-1-phenyl-2-propyl acetate (**2**; Table 2) or (*R,S*)-1-phenyl-2-butyl acetate (**3**; Table 3) with the recombinant PLE in comparison to reactions with PLE preparations from Fluka, Sigma, or Roche Diagnostics (Chirazyme E1 or E2). In the hydrolysis of **3**, these preparations showed only very low enantioselectivities ( $E = 1.4$ – $4.0$ ), whereas  $E$  values much greater than 100 were determined with recombinant PLE (Table 3). For **2**, this increase of enantioselectivity was less pronounced, but here we observed an inversion of enantiopreference (Table 2). With commercial esterases the *R* alcohol was preferentially formed, whereas with rPLE the *S* alcohol was produced. These results can be explained by the fact that we cloned the  $\gamma$  subunit of PLE,<sup>[13]</sup> but commercial




Figure 1. Comparison of the hydrolytic activity ( $A_{rel}$ ) of recombinant PLE (rPLE) with commercial preparations from Fluka and Roche Diagnostics (Chirazyme E2) towards different achiral esters.

Table 1. Enantioselectivity of different pig liver esterases in the kinetic resolution of **1**.

PLE <sup>[a]</sup>	<i>t</i> [h]	Enantiomeric excess ( <i>ee</i> )		Conversion [%]	<i>E</i> <sup>[b]</sup>
		<i>ee<sub>S</sub></i> [%] <sup>[c]</sup>	<i>ee<sub>P</sub></i> [%] <sup>[c]</sup>		
recombinant	1	58	53	53	5.7
Fluka	1.5	65	56	54	6.8
Sigma	1	72	58	55	7.8
Chirazyme E1	5	73	58	56	7.9

[a] In all reactions 0.5 U of esterase (based on pNPA-assay) were used. [b] The enantioselectivity  $E$  was calculated according to the method of Chen et al. (1982).<sup>[15]</sup> [c]  $ee_S$  = enantiomeric excess of the nonconverted substrate,  $ee_P$  = enantiomeric excess of the product. In all cases the product alcohol **1a** had *R* configuration and the nonconverted acetate **1** had *S* configuration.

Table 2. Enantioselectivity of different pig liver esterases in the kinetic resolution of **2**.

PLE <sup>[a]</sup>	<i>t</i> [h]	Enantiomeric excess		Conversion [%]	<i>E</i> <sup>[b]</sup>
		<i>ee<sub>S</sub></i> [%]	<i>ee<sub>P</sub></i> [%]		
recombinant	2	75 ( <i>R</i> )	70 ( <i>S</i> )	52	12.6
Fluka	1.5	35 ( <i>S</i> )	44 ( <i>R</i> )	44	3.6
Sigma	1.5	24 ( <i>S</i> )	32 ( <i>R</i> )	43	2.4
Chirazyme E1	1.5	22 ( <i>S</i> )	43 ( <i>R</i> )	34	3.1
Chirazyme E2	1	9 ( <i>S</i> )	9 ( <i>R</i> )	50	1.3

[a], [b] See Table 1.

Table 3. Enantioselectivity of different pig liver esterases in the kinetic resolution of **3**.

PLE <sup>[a]</sup>	<i>t</i> [h]	Enantiomeric excess		Conversion [%]	<i>E</i> <sup>[b]</sup>
		<i>ee<sub>S</sub></i> [%] <sup>[c]</sup>	<i>ee<sub>P</sub></i> [%] <sup>[c]</sup>		
Recombinant	2	57	> 99	36	>> 100
Fluka	2	12	12	49	1.4
Sigma	1	17	11	59	1.5
Chirazyme E-1	2	19	18	52	1.7
Chirazyme E-2	1	58	40	59	4.0

[a], [b] See Table 1. [c] In all cases the product alcohol **3a** had *S* configuration and the nonconverted acetate **3** had *R* configuration.

preparations are a mixture of subunits, which differ considerably in sequence and molecular weight.<sup>[5]</sup> This, of course, can also effect substrate selectivity and enantioselectivity.

Thus, the application of recombinant PLE now also allows the synthesis, in high optical purity, of compounds which have so far not been accessible by PLE-catalyzed reactions. Furthermore, the successful functional expression now makes the manipulation of enzyme properties by site-directed mutagenesis or directed evolution<sup>[16]</sup> feasible.

## Experimental Section

**Production of recombinant pig liver esterase (rPLE):** For expression of rPLE, the yeast *Pichia pastoris*—bearing the genomic-integrated gene that encodes the esterase under the control of the methanol-inducible alcohol oxidase 1 promotor (AOX1)—was grown according to the protocol given by the manufacturer (Invitrogen, Carlsbad, CA, USA), first in BMGY media containing glycerol (1% (v/v)) and then in BMMY media that contained methanol (0.5% (v/v)) as the carbon source and inducer. Induction of rPLE expression was maintained by daily addition of methanol (0.5% (v/v)). After 96 h, the cells were removed by centrifugation and the supernatant was concentrated for 15 min at 4000 g with 20 mL Centricons (NMWL 30000, Ultracel-PL membrane, Millipore). The activity thus obtained was 10 U mL<sup>-1</sup> (pNPA-assay), which corresponds to ~500 U mg<sup>-1</sup> protein.

**Determination of esterase activity:** Photometric determination of esterase activity was performed by hydrolysis of *p*-nitrophenyl acetate (pNPA).<sup>[7d]</sup> One unit (U) of esterase corresponds to the amount of enzyme that releases 1 μmol of *p*-nitrophenol per min.

The substrate spectrum of PLE was measured with a pH-Stat (Schott, Mainz, Germany) by hydrolysis of different esters (caprylic acid ethylester, acetic acid ethylester, tributyrin, or triolein) at 37 °C and pH 7.5.<sup>[7d]</sup> One unit (U) of esterase corresponds to the amount of enzyme that releases 1 μmol of acid per min. The thus-determined highest activity was set as the 100% value.

**Esterase-catalyzed kinetic resolution of the acetates:** Acetates **1–3** (10 mM) were dissolved in sodium phosphate buffer (pH 7.5, 50 mM) in 1-mL reaction vials and the kinetic resolution was started by addition of esterase (0.5 U, based on the pNPA assay). To stop the reaction, the mixture was extracted with dichloromethane and the organic phase was dried over anhydrous sodium sulfate. The determination of enantiomeric purity and conversion was performed by gas chromatography (column: heptakis(2,6-*O*-methyl-3-*O*-pentyl)-β-cyclodextrin; carrier gas: H<sub>2</sub>; flame ionization detector).

**Retention times [min]:** **1** (100 °C isothermal): (S)-**1** 3.7 min, (R)-**1** 5.8 min, (R)-**1a** 6.7 min, (S)-**1a** 7.6 min; **2** (75 °C isothermal): (S)-**2** 26.5 min, (R)-**2** 42.3 min, (S)-**2a** 32.6 min, (R)-**2a** 34.2 min; **3** (90 °C isothermal): (S)-**3** 17.6 min, (R)-**3** 20.2 min, (S)-**3a** 24.8 min, (R)-**3a** 27.4 min. The absolute configurations given for **1** are based on comparison with commercial (R)-**1a**. In case of **2** and **3** the *R* preference of the lipase Amano PS, as recorded in the literature,<sup>[17]</sup> served as the reference.

Received: December 13, 2000 [Z16264]

Publication delayed at author's request

- [1] a) U. T. Bornscheuer, R. J. Kazlauskas, *Hydrolases in Organic Synthesis—Regio- and Stereoselective Biotransformations*, Wiley-VCH, Weinheim, 1999; b) R. D. Schmid, R. Verger, *Angew. Chem.* **1998**, *110*, 1694–1720; *Angew. Chem. Int. Ed.* **1998**, *37*, 1608–1633; c) K. Faber, *Biotransformations in Organic Chemistry*, Springer, Berlin, 2000.
- [2] a) L.-M. Zhu, M. C. Tedford, *Tetrahedron* **1990**, *46*, 6587–6611; b) J. B. Jones, *Pure Appl. Chem.* **1990**, *62*, 1445–1448; c) C. Tamm, *Indian J. Chem. Sect. B* **1993**, *32*, 190–194; d) S. J. Phytian in *Biotechnology*, Vol. 8a (Eds.: H.-J. Rehm, G. Reed, A. Pühler, P. J. W. Stadler, D. R. Kelly), Wiley-VCH, Weinheim, 1998, pp. 193–241.
- [3] D. Seebach, M. Eberle, *Chimia* **1986**, *40*, 315–318.
- [4] D. Farb, W. D. Jencks, *Arch. Biochem. Biophys.* **1980**, *203*, 214–226.

- [5] a) E. Heymann, W. Junge, *Eur. J. Biochem.* **1979**, *95*, 509–518; b) W. Junge, E. Heymann, *Eur. J. Biochem.* **1979**, *95*, 519–525; c) N. Öhrner, A. Mattson, T. Norin, K. Hult, *Biocatalysis* **1990**, *4*, 81–88.
- [6] L. K. P. Lam, C. M. Brown, B. deJeso, L. Lym, E. J. Toone, J. B. Jones, *J. Am. Chem. Soc.* **1988**, *110*, 4409–4411.
- [7] a) V. Khalameyzer, U. T. Bornscheuer, *Biotechnol. Lett.* **1999**, *21*, 101–104; b) N. Krebsfänger, F. Zocher, J. Altenbuchner, U. T. Bornscheuer, *Enzyme Microb. Technol.* **1998**, *21*, 641–646; c) M. Nishizawa, M. Shimizu, H. Ohkawa, M. Kanaoka, *Appl. Environ. Microbiol.* **1995**, *61*, 3208–3215; d) V. Khalameyzer, I. Fischer, U. T. Bornscheuer, J. Altenbuchner, *Appl. Environ. Microbiol.* **1999**, *65*, 477–482.
- [8] a) D. T. Quyen, C. Schmidt-Dannert, R. D. Schmid, *Appl. Environ. Microbiol.* **1999**, *65*, 787–794; b) E. Catoni, C. Schmidt-Dannert, S. Brocca, R. D. Schmid, *Biotechnol. Tech.* **1997**, *11*, 689–695; c) B. Høge-Jensen, F. Andreassen, T. Christensen, M. Christensen, L. Thim, E. Boel, *Lipids* **1989**, *24*, 781–785.
- [9] a) T. Takahashi, A. Ikai, K. Takahashi, *J. Biol. Chem.* **1989**, *264*, 11565–11571; b) T. Takahashi, M. Nishigai, A. Ikai, K. Takahashi, *FEBS Lett.* **1991**, *280*, 297–300.
- [10] M. Matsushima, H. Inoue, M. Ichinose, S. Tsukada, K. Miki, K. Kurokawa, T. Takahashi, K. Takahashi, *FEBS Lett.* **1991**, *293*, 37–41.
- [11] E. Heymann, K. Peter, *Biol. Chem. Hoppe-Seyler* **1993**, *374*, 1033–1036.
- [12] L. David, X. J. Guo, C. Villard, A. Moulin, A. Puigserver, *Eur. J. Biochem.* **1998**, *257*, 142–148.
- [13] For the strategy used in the cloning and expression of rPLE, see: S. Lange, A. Musidlowska, C. Schmidt-Dannert, J. Schmitt, U. T. Bornscheuer, *ChemBioChem*, **2001**, *2*, 576–582.
- [14] For comparison, PLE preparations from Fluka, Sigma, and Roche Diagnostics (Chirazyme E1, E2) were used.
- [15] C. S. Chen, Y. Fujimoto, G. Girdaukas, C. J. Sih, *J. Am. Chem. Soc.* **1982**, *104*, 7294–7299.
- [16] a) U. T. Bornscheuer, *Biocatal. Biotransform.* **2001**, *19*, 84–96; b) U. T. Bornscheuer, *Angew. Chem.* **1998**, *110*, 3285–3288; *Angew. Chem. Int. Ed.* **1998**, *37*, 3105–3108; c) F. H. Arnold, *Acc. Chem. Res.* **1998**, *31*, 125–131.
- [17] A. L. Gutman, D. Brenner, A. Boltanski, *Tetrahedron: Asymmetry* **1993**, *4*, 839–844.

## Hydrolysis/Polycondensation in the Solid State: Access to Crystalline Silica-Based Hybrid Materials\*\*

Bruno Boury,\* Frédéric Ben, and Robert J. P. Corriu

Silicon-based hybrid materials allow the association at the molecular level of the properties of an organic group with the specific properties of a Si–O–Si network (transparency, chemical and thermal stability).<sup>[1–6]</sup> They are generally prepared by hydrolytic polycondensation from organic units covalently bound to trialkoxysilyl groups (Si(OR')<sub>3</sub>, R') = Me

[\*] Dr. B. Boury, F. Ben, Prof. R. J. P. Corriu  
Laboratoire de Chimie Moléculaire et Organisation du Solide  
UMR 5637, Université de Montpellier II  
Place E. Bataillon, 34095 Montpellier Cedex 5 (France)  
Fax: (+33)467-143-852  
E-mail: boury@crit.univ-montp2.fr

[\*\*] The authors are grateful to Dr. C. Dumas from the LBS laboratory at the Université de Montpellier I for the two-dimensional X-ray analysis.